Central Nervous System News and Research

RSS

SCCA, ProCure announce opening of Seattle Cancer Care Alliance Proton Therapy

Seattle Cancer Care Alliance (SCCA) and ProCure Treatment Centers, Inc. (ProCure) announced the opening of Seattle Cancer Care Alliance Proton Therapy, A ProCure Center today in Seattle, Washington.

8 Mar 2013

Study reveals increased dietary salt intake may lead to autoimmune disorders

Increased dietary salt intake can induce a group of aggressive immune cells that are involved in triggering and sustaining autoimmune diseases.

7 Mar 2013

Study suggests more accurate way to monitor patient awareness during general anesthesia

Massachusetts General Hospital investigators have identified specific EEG signatures that indicate when patients lose and regain consciousness under the general anesthetic drug propofol.

7 Mar 2013

Overall risk of infection associated with most neuroangiographic procedures is very low

Patients undergoing cerebral angiography and neurointerventional procedures on the brain are at very low risk of infection-even without preventive antibiotics, reports a study in the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

5 Mar 2013

Combination of two environmental factors contributes to schizophrenia

The interplay between an infection during pregnancy and stress in puberty plays a key role in the development of schizophrenia, as behaviourists from ETH Zurich demonstrate in a mouse model. However, there is no need to panic.

2 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

Researchers to discuss health issues at Society of Toxicology's Annual Meeting and ToxExpo

Researchers will meet at the Society of Toxicology's Annual Meeting and ToxExpo March 10-16 to discuss a number of health concerns that have received growing public attention over the past several months.

27 Feb 2013

Cleveland Clinic receives $1.97M NIMH grant for innovative autism research

The National Institute of Mental Health (NIMH) has awarded $1.97 million for innovative autism research to Bruce Trapp, Ph.D., Chairman of Neurosciences at Cleveland Clinic's Lerner Research Institute.

26 Feb 2013

Systemic delivery of antisense oligonucleotides neutralizes mutant RNA toxicity in mice with DM1

By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.

25 Feb 2013

Targeting CSF1R with selective inhibitors could help Alzheimer's

Scientists from the University of Southampton have identified the molecular system that contributes to the harmful inflammatory reaction in the brain during neurodegenerative diseases.

22 Feb 2013

Disruption in the body's circadian rhythm can increase risk of diabetes, heart disease

Disruption in the body's circadian rhythm can lead not only to obesity, but can also increase the risk of diabetes and heart disease.

22 Feb 2013

Imatinib can relieve and slow down progression of multiple sclerosis

A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE.

21 Feb 2013

Targeting p38alpha MAPK isoform can help treat CNS inflammatory diseases

A study by a leading Alzheimer's researcher at the University of Kentucky provides new evidence that will help researchers home in on the molecular mechanisms involved in inflammation of the central nervous system (CNS) and aid drug-development strategies for treating inflammatory neurological diseases.

20 Feb 2013

New lab at Diamond to help scientists delve into inner workings of pathogens

The UK's national synchrotron facility, Diamond Light Source, is now the first and only place in Europe where pathogens requiring Containment Level 3 - including serious viruses such as those responsible for AIDS, Hepatitis and some types of flu - can be analysed at atomic and molecular level using synchrotron light.

18 Feb 2013

FDA committee recommends approval of Guerbet’s Dotarem NDA for adults and children

Guerbet, the contrast agent specialist for medical imaging, today announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older.

15 Feb 2013

Allografts better survive implantation into brains of immunocompetent research mice

Researchers at the Johns Hopkins University in Baltimore, Md., and the Mossakowski Medical Research Centre in Warsaw, Poland, have found that nonself-donated cells (allografts) better survive implantation into the brains of immunocompetent research mice when the grafts are injected into the striatum (STR) of the brain rather than injected into the forceps minor (FM) region.

14 Feb 2013

AACN recognizes 98 Beacon-designated units from 78 hospitals

The American Association of Critical-Care Nurses (AACN) recognizes 98 units from 78 hospitals nationwide that earned the Beacon Award for Excellence between Jan. 1, 2012, and Dec. 31, 2012.

13 Feb 2013

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

House Research Institute (HRI) is recruiting patients for a Phase II clinical trial to test a medication that may slow the progression of Neurofibromatosis Type-2, commonly referred to as NF2.

13 Feb 2013

Study finds abnormal production of C9RANT in patients with ALS, frontotemporal dementia

Researchers at Mayo Clinic have discovered an abnormal protein that accumulates in the brains of many patients affected with two common neurodegenerative disorders — amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and frontotemporal dementia.

13 Feb 2013

Reprogrammed human skin cells highly effective in treating myelin disorders

A study out today in the journal Cell Stem Cell shows that human brain cells created by reprogramming skin cells are highly effective in treating myelin disorders, a family of diseases that includes multiple sclerosis and rare childhood disorders called pediatric leukodystrophies.

10 Feb 2013

Central Nervous System News and Research

SCCA, ProCure announce opening of Seattle Cancer Care Alliance Proton Therapy

Study reveals increased dietary salt intake may lead to autoimmune disorders

Study suggests more accurate way to monitor patient awareness during general anesthesia

Overall risk of infection associated with most neuroangiographic procedures is very low

Combination of two environmental factors contributes to schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Researchers to discuss health issues at Society of Toxicology's Annual Meeting and ToxExpo

Cleveland Clinic receives $1.97M NIMH grant for innovative autism research

Systemic delivery of antisense oligonucleotides neutralizes mutant RNA toxicity in mice with DM1

Targeting CSF1R with selective inhibitors could help Alzheimer's

Disruption in the body's circadian rhythm can increase risk of diabetes, heart disease

Imatinib can relieve and slow down progression of multiple sclerosis

Targeting p38alpha MAPK isoform can help treat CNS inflammatory diseases

New lab at Diamond to help scientists delve into inner workings of pathogens

FDA committee recommends approval of Guerbet’s Dotarem NDA for adults and children

Allografts better survive implantation into brains of immunocompetent research mice

AACN recognizes 98 Beacon-designated units from 78 hospitals

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

Study finds abnormal production of C9RANT in patients with ALS, frontotemporal dementia

Reprogrammed human skin cells highly effective in treating myelin disorders

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News